Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,400 GBX | -0.36% | -0.36% | +105.88% |
Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Sales 2021 | 338K 431K | Sales 2022 | 268K 341K | Capitalization | 87.45M 111M |
---|---|---|---|---|---|
Net income 2021 | -3M -3.82M | Net income 2022 | -5M -6.37M | EV / Sales 2021 | 200 x |
Net cash position 2021 | 8.06M 10.26M | Net cash position 2022 | 1.24M 1.58M | EV / Sales 2022 | 322 x |
P/E ratio 2021 |
-23.4
x | P/E ratio 2022 |
-17
x | Employees | 78 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 30.4% |
1 day | -0.36% | ||
1 week | -0.36% | ||
1 month | +30.23% | ||
3 months | +57.30% | ||
6 months | +147.79% | ||
Current year | +105.88% |
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 46 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Director/Board Member | 53 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1,400 | -0.36% | 2,627 |
24-05-30 | 1,405 | -.--% | 1,635 |
24-05-29 | 1,405 | -.--% | 5,369 |
24-05-28 | 1,405 | -.--% | 2,808 |
24-05-24 | 1,405 | -.--% | 294 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+105.88% | 228M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- 4BB Stock